

## Incidence of post-cesarean surgical site infection with cefazolin alone versus cefazolin plus azithromycin prophylaxis. A hospital-based observational cohort study.

Dr Vidyullatha Balivada<sup>1</sup>, Dr Usharani Nagarapu<sup>2</sup>, Dr Akula Swaroopa Rani<sup>2\*</sup>, Dr Prashanth Kumar Patnaik<sup>3</sup>

<sup>1</sup>Assistant Professor, Department of Pharmacology, RVM Institute of Medical Sciences and Research Centre, Laxmakkapally, Mulugu Mandal, Siddipet District, Telangana, India

<sup>2</sup>Associate Professor, Department of Obstetrics & Gynaecology, RVM Institute of Medical Sciences and Research Centre, Laxmakkapally, Mulugu Mandal, Siddipet District, Telangana, India

<sup>3</sup>Associate Professor, Department of Pharmacology, RVM Institute of Medical Sciences and Research Centre, Laxmakkapally, Mulugu Mandal, Siddipet District, Telangana, India

Page | 1

### Abstract

#### Background

Surgical site infection after cesarean delivery remains a significant cause of maternal morbidity, prolonged hospitalization, readmission, and increased treatment cost.

#### Objectives

To compare the 30-day cumulative incidence of post-cesarean surgical site infection between women receiving cefazolin alone and those receiving cefazolin plus azithromycin, and to identify clinical factors associated with infection.

#### Methods

This hospital-based observational cohort study was conducted at a tertiary care teaching hospital in Telangana, India. A total of 100 women undergoing cesarean delivery were enrolled and categorized according to prophylaxis received: cefazolin alone [n=50] or cefazolin plus azithromycin [n=50]. The primary outcome was surgical site infection within 30 days. Secondary outcomes included febrile morbidity, prolonged hospital stay, readmission due to infection, need for resuturing or drainage, and postoperative wound discharge. Demographic, obstetric, and perioperative variables were also assessed.

#### Results

Baseline demographic and obstetric characteristics were comparable between groups. During 30-day follow-up, 10 of 100 women developed surgical site infection, yielding a cumulative incidence of 10.0%. Infection occurred in 14.0% of the cefazolin-alone group and 6.0% of the combination group, with an absolute risk difference of 8.0 percentage points; however, the difference was not statistically significant [p=0.18]. Superficial incisional infection was the most frequent type [7.0%], followed by deep incisional infection [2.0%] and organ/space infection [1.0%]. Secondary infectious outcomes were consistently lower in the combination group. Surgical site infection was significantly associated with BMI  $\geq 30$  kg/m<sup>2</sup>, rupture of membranes >12 hours, and operative duration >60 minutes.

#### Conclusion

Cefazolin plus azithromycin prophylaxis was associated with a lower 30-day risk of post-cesarean surgical site infection and fewer postoperative infectious complications than cefazolin alone. Although the difference was not statistically significant, the overall trend favored adjunctive azithromycin.

#### Recommendation

Larger multicenter prospective studies are recommended to validate these findings and guide prophylactic antibiotic strategies for high-risk cesarean deliveries.

**Keywords:** cesarean delivery; surgical site infection; cefazolin; azithromycin; antibiotic prophylaxis; observational cohort.

**Submitted:** December 20, 2025 **Accepted:** January 20, 2026 **Published:** February 10, 2026

#### Corresponding Author

Dr Akula Swaroopa Rani

Email: [swaroopahospital@gmail.com](mailto:swaroopahospital@gmail.com)

Associate Professor, Department of Obstetrics & Gynaecology, RVM Institute of Medical Sciences and Research Centre, Laxmakkapally, Mulugu Mandal, Siddipet Dist, Telangana, India

### Introduction

Cesarean delivery is one of the most frequently performed operative procedures in obstetric practice, and its use has increased steadily across many regions, including low- and middle-income countries [8]. Despite its life-saving role for

both mother and fetus, cesarean delivery is also associated with a substantial postoperative infectious burden, of which surgical site infection is among the most relevant complications [9-14]. Post-cesarean surgical site infection can prolong recovery, increase antibiotic exposure, delay ambulation and

breastfeeding comfort, necessitate repeat visits or readmission, and impose additional economic pressure on families and institutions [13,14]. For maternity services in busy tertiary care centers, even a modest reduction in preventable postoperative infection carries practical significance.

The pathogenesis of post-cesarean infection is multifactorial. Maternal obesity, anemia, emergency surgery, prolonged rupture of membranes, repeated vaginal examinations, longer operative duration, hematoma formation, and preexisting intrapartum infection have all been linked with increased postoperative wound morbidity [8-12]. The bacterial milieu in cesarean delivery is also broader than in many clean surgical procedures because the operative field is influenced by skin flora, genital tract organisms, and, in some women, ascending polymicrobial contamination. For this reason, perioperative antibiotic prophylaxis remains a cornerstone of infection prevention, alongside standardized skin preparation, sterile operative technique, and timely postoperative surveillance [7,13,14].

Cefazolin has long been used as standard prophylaxis for cesarean delivery because of its safety profile, spectrum against common skin organisms, ease of administration, and established role in obstetric surgery [7,13,14]. However, concern persists that cefazolin alone may provide incomplete coverage against ureaplasma and other genital tract organisms implicated in endometritis and wound infection. This concern prompted interest in extended-spectrum regimens, especially the addition of azithromycin. Important randomized and observational studies have shown lower rates of postoperative infection with adjunctive azithromycin in selected cesarean populations, and subsequent systematic reviews and meta-analyses have generally supported a reduction in infectious morbidity with broader prophylaxis [1-6]. Even so, outcome magnitude varies across studies because of differences in patient selection, labor status, membrane rupture, institutional protocols, and baseline infection risk.

Contemporary data from Indian tertiary care settings remain comparatively limited, and local observational evidence is valuable because antibiotic policy, patient risk profiles, and perioperative care pathways differ across institutions [4,8]. In this context, the present study was undertaken at RVM Institute of Medical Sciences and Research Centre, Laxmakkapally, Telangana, to compare the incidence of post-cesarean surgical site infection among women who received cefazolin alone versus cefazolin plus azithromycin prophylaxis. The secondary objectives were to compare early postoperative infectious and hospital-related outcomes between the two prophylaxis groups and to identify selected clinical factors associated with surgical site infection in the study cohort.

## Methodology

### Study design and setting

This hospital-based observational cohort study was conducted in the Department of Obstetrics and Gynecology at RVM

Institute of Medical Sciences and Research Centre, Laxmakkapally, Telangana, India, a tertiary care teaching hospital. The study was carried out over eight months, from March 2025 to October 2025. Institutional ethics committee clearance was obtained before initiation of the study. Women were enrolled consecutively during the study period, and the final analytical sample comprised 100 eligible participants.

### Study population

Pregnant women who underwent cesarean delivery during the study period and received perioperative prophylaxis with either cefazolin alone or cefazolin plus azithromycin were considered eligible. Women were included if they had complete perioperative records and postoperative follow-up documentation sufficient for surgical site infection surveillance. Patients with established systemic infection requiring therapeutic broad-spectrum antibiotics before surgery, major immunocompromised states, re-laparotomy for noninfective indications, or incomplete records were excluded. Because this was an observational cohort, allocation to prophylactic regimen was based on the treating unit's routine practice and the antibiotic actually administered rather than random assignment.

### Study size

The sample size was determined based on the expected proportion of surgical site infection following cesarean delivery reported in previous hospital-based studies. Assuming an anticipated infection proportion of approximately 10%, a 95% confidence level, and a margin of error of 6%, the required minimum sample size was calculated using the standard formula for single-proportion studies:

$$n = Z^2 \times p \times (1 - p) / d^2$$

where  $n$  represents the required sample size,  $Z$  is the standard normal deviate corresponding to a 95% confidence level [1.96],  $p$  is the expected prevalence of surgical site infection [0.10], and  $d$  is the acceptable margin of error [0.06]. The calculated sample size was approximately 96 participants. This was rounded to 100 participants to improve statistical precision and ensure equal allocation into two comparison groups [50 participants in each group].

### Exposure and perioperative prophylaxis

Participants were categorized into two equal cohorts according to the prophylaxis received: Group A received cefazolin alone ( $n=50$ ), and Group B received cefazolin plus azithromycin ( $n=50$ ). In routine perioperative practice, intravenous prophylaxis was administered within the accepted preincision window. Standard preoperative preparation, cesarean technique, skin closure, and postoperative ward care followed institutional practice. Baseline demographic details, parity, gestational age, type of cesarean section, duration of surgery, body mass index, anemia status, rupture of membranes, and

selected perioperative variables were recorded from case sheets, operation theater records, and inpatient notes.

recorded and analyzed to control for potential confounding factors.

### Outcome measures

The primary outcome was post-caesarean surgical site infection occurring within 30 days of surgery, classified according to Centers for Disease Control and Prevention criteria as superficial incisional, deep incisional, or organ/space infection [13]. Secondary outcomes were febrile morbidity, prolonged hospital stay longer than 5 days, readmission due to infection, need for resuturing or drainage, and postoperative wound discharge. Postoperative surveillance was performed during hospitalization and through documented follow-up visits or return consultations within the surveillance window.

### Bias.

Several measures were implemented to minimize potential sources of bias. Selection bias was reduced by enrolling consecutive eligible women undergoing cesarean delivery during the study period who met the predefined inclusion and exclusion criteria. Standardized clinical definitions for surgical site infection based on internationally accepted criteria were used to ensure uniform outcome assessment. Data collection was performed using a structured proforma to maintain consistency. Additionally, all participants were followed for a uniform postoperative period of 30 days to reduce outcome ascertainment bias. Clinical variables such as body mass index, duration of rupture of membranes, and operative duration were

### Statistical analysis.

Data were entered in a structured spreadsheet and analyzed using standard statistical methods. Categorical variables were summarized as frequencies and percentages, whereas continuous variables were expressed as mean with standard deviation. Between-group comparisons for categorical variables were performed using the chi-square test or Fisher exact test as appropriate, and continuous variables were compared using the independent samples t test. Risk-factor analysis compared women with and without surgical site infection. A p value of less than 0.05 was considered statistically significant.

### Results

A total of 100 women undergoing cesarean delivery were included in the analysis, with 50 women in the cefazolin-alone cohort and 50 in the cefazolin-plus-azithromycin cohort. Baseline demographic and obstetric characteristics were comparable between the two groups. Age distribution was similar, and the mean age was  $27.6 \pm 4.2$  years in the cefazolin-alone group and  $26.9 \pm 4.5$  years in the combination group. Parity profile, gestational age at delivery, type of cesarean section, and mean duration of surgery also did not differ significantly between groups, indicating reasonable baseline comparability of the two cohorts [Table 1].

**Table 1. Baseline demographic and obstetric characteristics of the study participants**

Variable	Cefazolin alone (n = 50)	Cefazolin + Azithromycin (n = 50)	Total (N = 100)	p-value
<b>Age group (years)</b>				<b>0.78</b>
18-20	6 (12.0%)	7 (14.0%)	13 (13.0%)	
21-25	18 (36.0%)	20 (40.0%)	38 (38.0%)	
26-30	17 (34.0%)	15 (30.0%)	32 (32.0%)	
>30	9 (18.0%)	8 (16.0%)	17 (17.0%)	
Mean age (years)	$27.6 \pm 4.2$	$26.9 \pm 4.5$	$27.3 \pm 4.3$	0.42
<b>Parity</b>				<b>0.69</b>
Primigravida	24 (48.0%)	22 (44.0%)	46 (46.0%)	
Multigravida	26 (52.0%)	28 (56.0%)	54 (54.0%)	
<b>Gestational age at delivery</b>				<b>0.81</b>
37-38 weeks	16 (32.0%)	18 (36.0%)	34 (34.0%)	
39-40 weeks	27 (54.0%)	25 (50.0%)	52 (52.0%)	
>40 weeks	7 (14.0%)	7 (14.0%)	14 (14.0%)	

Variable	Cefazolin alone (n = 50)	Cefazolin + Azithromycin (n = 50)	Total (N = 100)	p-value
<b>Type of cesarean section</b>				<b>0.67</b>
Elective	20 (40.0%)	22 (44.0%)	42 (42.0%)	
Emergency	30 (60.0%)	28 (56.0%)	58 (58.0%)	
Mean duration of surgery (minutes)	57.8 ± 10.4	55.9 ± 9.8	56.9 ± 10.1	0.35

The overall incidence of post-cesarean surgical site infection in the study population was 10.0% (10/100). Surgical site infection occurred in 7 women (14.0%) who received cefazolin alone and in 3 women (6.0%) who received cefazolin plus azithromycin. Thus, the crude infection rate was lower in the combination group, although the between-group difference

was not statistically significant (p=0.18). Superficial incisional surgical site infection was the most common infection category in both cohorts, while deep incisional infection was infrequent and only one organ/space infection was documented in the entire study population [Table 2].

**Table 2. Incidence and pattern of post-cesarean surgical site infection**

Outcome	Cefazolin alone (n = 50)	Cefazolin + Azithromycin (n = 50)	Total (N = 100)	p-value
Any surgical site infection	7 (14.0%)	3 (6.0%)	10 (10.0%)	0.18
No surgical site infection	43 (86.0%)	47 (94.0%)	90 (90.0%)	
<b>Type of surgical site infection</b>				
Superficial incisional SSI	5 (10.0%)	2 (4.0%)	7 (7.0%)	
Deep incisional SSI	1 (2.0%)	1 (2.0%)	2 (2.0%)	
Organ/space infection (endometritis)	1 (2.0%)	0 (0.0%)	1 (1.0%)	

Other postoperative infectious and hospital-related outcomes followed a similar pattern. Febrile morbidity was recorded in 12.0% of women in the cefazolin-alone group compared with 6.0% in the cefazolin-plus-azithromycin group. Prolonged hospital stay beyond 5 days occurred in 16.0% and 8.0% of

women, respectively. Readmission due to infection, need for resuturing or drainage, and postoperative wound discharge were also less frequent in the combination group, although these differences were not statistically significant [Table 3].

**Table 3. Postoperative infectious and hospital-related outcomes**

Outcome	Cefazolin alone (n = 50)	Cefazolin + Azithromycin (n = 50)	Total (N = 100)	p-value
Febrile morbidity	6 (12.0%)	3 (6.0%)	9 (9.0%)	0.29
Prolonged hospital stay (>5 days)	8 (16.0%)	4 (8.0%)	12 (12.0%)	0.22
Readmission due to infection	2 (4.0%)	1 (2.0%)	3 (3.0%)	0.56
Need for resuturing/drainage	1 (2.0%)	0 (0.0%)	1 (1.0%)	0.31
Postoperative wound discharge	6 (12.0%)	2 (4.0%)	8 (8.0%)	0.14

Risk-factor analysis demonstrated that body mass index of 30 kg/m<sup>2</sup> or higher, prolonged rupture of membranes beyond 12 hours, and operative duration greater than 60 minutes were significantly associated with surgical site infection.

Emergency cesarean section and anemia were numerically more common among women who developed infection, but these associations were not statistically significant in this cohort [Table 4].

**Table 4. Association of selected clinical risk factors with surgical site infection**

Risk factor	SSI present (n = 10)	SSI absent (n = 90)	Total (N = 100)	p-value
BMI ≥30 kg/m <sup>2</sup>	4 (40.0%)	16 (17.8%)	20 (20.0%)	0.048
Prolonged rupture of membranes (>12 hours)	5 (50.0%)	19 (21.1%)	24 (24.0%)	0.031
Duration of surgery >60 minutes	6 (60.0%)	28 (31.1%)	34 (34.0%)	0.041
Emergency cesarean section	7 (70.0%)	51 (56.7%)	58 (58.0%)	0.39
Anemia (Hb <10 g/dL)	4 (40.0%)	22 (24.4%)	26 (26.0%)	0.28

## Discussion

The present hospital-based observational cohort study showed a lower crude proportion of post-cesarean surgical site infection in women receiving cefazolin plus azithromycin than in those receiving cefazolin alone [6.0% vs 14.0%]. This finding supports the possible benefit of adjunctive azithromycin in broadening antimicrobial coverage against polymicrobial genital tract flora commonly implicated in post-cesarean infections. Although not statistically significant, the trend indicates a clinically meaningful reduction in postoperative infectious morbidity. Although the p value did not cross the threshold for statistical significance, the direction of effect across the primary outcome and several secondary outcomes consistently favored the combination regimen. This overall pattern is clinically meaningful because surgical site infection after cesarean delivery has consequences that extend beyond wound morbidity, including prolonged hospitalization, additional antibiotic exposure, greater need for follow-up care, and higher institutional cost [13,14].

This study findings are broadly in line with prior evidence supporting broader perioperative prophylaxis in cesarean delivery. The landmark trial by Tita et al. demonstrated a significant reduction in postoperative infection with adjunctive azithromycin in women undergoing nonelective cesarean delivery [1]. Subsequent observational studies also reported lower postpartum infectious morbidity after adoption of adjunctive azithromycin policies, including in prelabor cesarean births and broader institutional practice settings [2,3]. A randomized trial from India comparing cefazolin alone with cefazolin plus azithromycin showed favorable results for the combination regimen, reinforcing the relevance of this strategy in resource-variable settings [4]. In addition, systematic reviews and meta-analyses have generally confirmed reductions in wound infection, endometritis, and composite infectious outcomes with adjunctive prophylaxis [5-7]. The

present study adds local observational data from a tertiary care teaching hospital and shows a similar trend.

The absence of statistical significance in the primary comparison should be interpreted in light of sample size. With only 100 participants and 10 total infection events, the study had limited power to detect moderate between-group differences. Even so, the absolute difference of 8 percentage points between the two cohorts is notable from a practical perspective. The predominance of superficial incisional infection in this cohort also mirrors the usual clinical pattern reported in post-cesarean surveillance studies [8-12]. Importantly, febrile morbidity, prolonged hospital stay, and wound discharge were numerically lower in the combination group, supporting internal consistency of the observed protective direction.

These observations agree with previous literature identifying elevated body mass index, emergency or intrapartum exposure, prolonged membrane rupture, and operative complexity as important contributors to post-cesarean surgical site infection [8-12]. Obesity can impair tissue oxygenation and wound healing, prolonged membrane rupture increases bacterial exposure, and longer surgery often reflects more difficult procedures with greater tissue handling. Together, these findings suggest that broader antibiotic prophylaxis should be interpreted as one component of a larger infection-prevention bundle. Risk stratification, timely antibiotic administration, meticulous operative technique, and surveillance remain central to improving maternal postoperative outcomes [13,14].

## Generalizability

The findings of this hospital-based observational cohort study may be applicable to similar tertiary care settings, particularly in regions with comparable patient profiles, surgical practices, and infection control standards. The overall pattern of postoperative infectious outcomes observed in this study is

consistent with previously reported data from obstetric populations undergoing cesarean delivery. However, generalizability may be limited by the single-center design and relatively small sample size. Differences in institutional protocols, antibiotic stewardship policies, and patient risk profiles across healthcare settings should be considered when interpreting and applying these results to broader populations.

## Conclusion

In this hospital-based observational cohort, women who received cefazolin plus azithromycin prophylaxis had a lower incidence of post-cesarean surgical site infection than those who received cefazolin alone. The combination group also showed lower frequencies of febrile morbidity, prolonged hospital stay, readmission, and wound discharge. Although the primary between-group comparison was not statistically significant in this 100-patient sample, the overall direction of findings consistently favored adjunctive azithromycin. Obesity, prolonged rupture of membranes, and longer operative duration remained important correlates of infection. These findings support risk-aware perioperative prophylaxis, careful surveillance, and strengthened infection-prevention pathways, and they reinforce the rationale for larger prospective studies evaluating broader antibiotic coverage in cesarean delivery.

## Limitations

This single-center observational cohort included a modest sample, which limited statistical power and widened uncertainty around the between-group comparison. Regimen allocation followed routine clinical practice rather than randomization, so selection bias and residual confounding remained possible. Microbiological confirmation was not available for every infection episode, and post-discharge surveillance depended partly on follow-up documentation recorded in routine clinical care after hospital discharge.

## Recommendations.

Based on the findings of this study, the addition of azithromycin to standard cefazolin prophylaxis may be considered as a potentially beneficial strategy to reduce postoperative infectious complications following cesarean delivery, particularly among women with identified risk factors such as obesity, prolonged rupture of membranes, or prolonged operative duration. Further large-scale multicenter prospective studies are recommended to confirm these observations and to establish evidence-based guidelines for perioperative antibiotic prophylaxis in cesarean deliveries.

## Acknowledgment

The authors express their sincere gratitude to the Department of Obstetrics and Gynecology and the hospital administration for their support and cooperation during the conduct of this study. The authors also thank the nursing staff and all

participants who contributed to the successful completion of the research.

## List of Abbreviations

SSI – Surgical Site Infection

BMI – Body Mass Index

ROM – Rupture of Membranes

CS – Cesarean Section

IV – Intravenous

SD – Standard Deviation

CI – Confidence Interval

CDC – Centers for Disease Control and Prevention

## Source of Funding.

No funding was received.

## Conflict of Interest

The authors declare no conflict of interest.

## Data Availability

Data Available on request

## Author Contributions

Dr Vidyullatha Balivada contributed to study conceptualization, research design, data collection, statistical analysis, and preparation of the initial manuscript draft.

Dr Usharani Nagarapu participated in clinical supervision, patient recruitment, data acquisition, and critical review of the manuscript for important intellectual content.

Dr Akula Swaroopa Rani contributed to study coordination, interpretation of clinical findings, and revision of the manuscript.

Dr Prashanth Kumar Patnaik assisted in study design, pharmacological interpretation of antibiotic prophylaxis, data validation, and final manuscript editing.

## Author Biographies

**Dr Vidyullatha Balivada** is an Assistant Professor in the Department of Pharmacology at RVM Institute of Medical Sciences and Research Centre, Laxmakkapally, Siddipet District, Telangana, India. She is actively involved in

undergraduate and postgraduate medical teaching and clinical pharmacology research. Her academic interests include rational drug therapy, antimicrobial stewardship, and pharmacovigilance. She has participated in several institutional research projects and is committed to promoting evidence-based pharmacotherapy in clinical practice.

Page | 7

**Dr Usharani Nagarapu** is an Associate Professor in the Department of Obstetrics and Gynaecology at RVM Institute of Medical Sciences and Research Centre, Laxmakkapally, Siddipet District, Telangana, India. She has extensive clinical experience in maternal health, high-risk obstetrics, and gynecological practice. Her research interests focus on maternal morbidity, obstetric infections, and improving outcomes in cesarean deliveries. She is actively engaged in academic teaching, clinical training, and obstetric research.

**Dr Akula Swaroopa Rani** serves as an Associate Professor in the Department of Obstetrics and Gynaecology at RVM Institute of Medical Sciences and Research Centre, Laxmakkapally, Siddipet District, Telangana, India. She has significant experience in clinical obstetrics, reproductive health, and gynecological care. Her academic interests include maternal health research, obstetric complications, and evidence-based management of pregnancy-related disorders.

**Dr Prashanth Kumar Patnaik** is an Associate Professor in the Department of Pharmacology at RVM Institute of Medical Sciences and Research Centre, Laxmakkapally, Siddipet District, Telangana, India. His academic work focuses on antimicrobial pharmacology, drug safety, and clinical therapeutics. He is actively involved in teaching medical students and guiding research in pharmacology and rational prescribing practices.

## References

1. Tita ATN, Szychowski JM, Boggess K, Saade G, Longo S, Clark E, et al. Adjunctive azithromycin prophylaxis for cesarean delivery. *N Engl J Med*. 2016 Sep 29;375(13):1231-41. doi: 10.1056/NEJMoa1602044.
2. Ruzic MF, Blanchard CT, Cozzi GD, Howard HR, Casey BM, Tita AT, et al. Adjunctive azithromycin prophylaxis for prelabor cesarean birth. *Obstet Gynecol*. 2023 Feb 1;141(2):403-413. doi: 10.1097/AOG.0000000000005037.
3. Pierce SL, Bisson CM, Dubois ME, Grimes SB, Katz MS, Weed MM, et al. Clinical effectiveness of adding azithromycin to antimicrobial prophylaxis for cesarean delivery. *Am J Obstet Gynecol*. 2021 Sep;225(3):335.e1-335.e7. doi: 10.1016/j.ajog.2021.05.023.
4. Jyothi MS, Kalra JK, Arora A, Patil A, Suri V, Jain V, et al. Randomized controlled trial of cefazolin monotherapy versus cefazolin plus azithromycin single dose prophylaxis for cesarean deliveries: a developing country's perspective. *J Family Med Prim Care*. 2019 Sep 30;8(9):3015-3021. doi: 10.4103/jfmpc.jfmpc\_593\_19.
5. Markwei MT, Babatunde I, Rathi N, Fan C, Prah MA, Joo J, et al. Preincision adjunctive prophylaxis for cesarean deliveries: a systematic review and meta-analysis. *Am J Obstet Gynecol*. 2021 Oct;225(4):382.e1-382.e13. doi: 10.1016/j.ajog.2021.04.259.
6. Yang M, Yuan F, Guo Y, Wang S. Efficacy of adding azithromycin to antibiotic prophylaxis in caesarean delivery: a meta-analysis and systematic review. *Int J Antimicrob Agents*. 2022 Mar;59(3):106533. doi: 10.1016/j.ijantimicag.2022.106533.
7. Tita ATN, Rouse DJ, Blackwell S, Saade G, Spong CY, Andrews WW. Emerging concepts in antibiotic prophylaxis for cesarean delivery: a systematic review. *Obstet Gynecol*. 2009 Mar;113(3):675-682. doi: 10.1097/AOG.0b013e318197c3b6.
8. Basany K, Chaudhuri S, Lakshmi Shailaja P, Agiwal V, Angaali N, Nirupama AY, et al. Prospective cohort study of surgical site infections following single dose antibiotic prophylaxis in caesarean section at a tertiary care teaching hospital in Medchal, India. *PLoS One*. 2024 Jan 25;19(1):e0286165. doi: 10.1371/journal.pone.0286165.
9. Kvalvik SA, Rasmussen S, Thornhill HF, Baghestan E. Risk factors for surgical site infection following cesarean delivery: a hospital-based case-control study. *Acta Obstet Gynecol Scand*. 2021 Dec;100(12):2167-2175. doi: 10.1111/aogs.14235.
10. Farret TCF, Dallé J, Monteiro VDS, Riche CVW, Antonello VS. Risk factors for surgical site infection following cesarean section in a Brazilian Women's Hospital: a case-control study. *Braz J Infect Dis*. 2015 Mar-Apr;19(2):113-7. doi: 10.1016/j.bjid.2014.09.009.
11. Tran TS, Jamulitrat S, Chongsuvatwong V, Geater A. Risk factors for postcesarean surgical site infection. *Obstet Gynecol*. 2000 Mar;95(3):367-71. doi: 10.1016/S0029-7844(99)00540-2.
12. Olsen MA, Butler AM, Willers DM, Devkota P, Gross GA, Fraser VJ. Risk factors for surgical site infection after low transverse cesarean section. *Infect Control Hosp Epidemiol*. 2008 Jun;29(6):477-84; discussion 485-6. doi: 10.1086/587810.
13. Berríos-Torres SI, Umscheid CA, Bratzler DW, Leas B, Stone EC, Kelz RR, et al. Centers for Disease Control and Prevention guideline for the prevention of surgical site infection, 2017. *JAMA Surg*. 2017 Aug 1;152(8):784-791. doi: 10.1001/jamasurg.2017.0904.

14. Seidelman JL, Mantyh CR, Anderson DJ. Surgical site infection prevention: a review. JAMA. 2023 Jan 17;329(3):244-252. doi: 10.1001/jama.2022.24075.

#### Publisher details

## **Student's Journal of Health Research (SJHR)**

**(ISSN 2709-9997) Online**

**(ISSN 3006-1059) Print**

**Category: Non-Governmental & Non-profit Organization**

**Email: [studentsjournal2020@gmail.com](mailto:studentsjournal2020@gmail.com)**

**WhatsApp: +256 775 434 261**

**Location: Scholar's Summit Nakigalala, P. O. Box 701432,  
Entebbe Uganda, East Africa**

